$OMED Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in OncoMed Pharmaceuticals Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in OncoMed Pharmaceuticals Inc. Get notifications about new insider transactions in OncoMed Pharmaceuticals Inc for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP and General Cou ... | Sell | U | 0.00 | 39,488 | 0 | 0 | 39.5 K to 0 (-100.00 %) |
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | U | 0.00 | 121,020 | 0 | 0 | 121 K to 0 (-100.00 %) |
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Sell | U | 0.00 | 380,299 | 0 | 0 | 380.3 K to 0 (-100.00 %) |
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Sell | U | 0.00 | 1,119,905 | 0 | 0 | 1.1 M to 0 (-100.00 %) |
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Sell | U | 0.00 | 185,709 | 0 | 0 | 185.7 K to 0 (-100.00 %) |
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | President and CEO | Sell | U | 0.00 | 142,534 | 0 | 0 | 142.5 K to 0 (-100.00 %) |
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Sell | U | 0.00 | 18,940 | 0 | 0 | 18.9 K to 0 (-100.00 %) |
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Sell | U | 0.00 | 1,991,602 | 0 | 0 | 2 M to 0 (-100.00 %) |
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | Li Yvonne | See Remarks | Sell | U | 0.00 | 65,895 | 0 | 0 | 65.9 K to 0 (-100.00 %) |
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | Stagg Robert | See Remarks | Sell | U | 0.00 | 28,917 | 0 | 0 | 28.9 K to 0 (-100.00 %) |
Apr 23 2019 | OMED | OncoMed Pharmaceut ... | KARSEN PERRY A | Director | Sell | U | 0.00 | 80,500 | 0 | 0 | 80.5 K to 0 (-100.00 %) |
Dec 26 2018 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 0.60 | 11,117 | 6,669 | 66,807 | 77.9 K to 66.8 K (-14.27 %) |
Oct 11 2018 | OMED | OncoMed Pharmaceut ... | Stagg Robert | SVP, Clinical R&D | Sell | S | 2.01 | 927 | 1,863 | 40,670 | 41.6 K to 40.7 K (-2.23 %) |
Oct 11 2018 | OMED | OncoMed Pharmaceut ... | Li Yvonne | See Remarks | Sell | S | 2.02 | 927 | 1,873 | 59,734 | 60.7 K to 59.7 K (-1.53 %) |
Oct 11 2018 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 2.01 | 1,156 | 2,324 | 77,924 | 79.1 K to 77.9 K (-1.46 %) |
Oct 11 2018 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Sell | S | 2.02 | 1,156 | 2,335 | 51,754 | 52.9 K to 51.8 K (-2.18 %) |
Oct 11 2018 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | President & CEO | Sell | S | 2.01 | 1,156 | 2,324 | 55,966 | 57.1 K to 56 K (-2.02 %) |
Oct 10 2018 | OMED | OncoMed Pharmaceut ... | Li Yvonne | See Remarks | Sell | S | 2.13 | 1,229 | 2,616 | 60,661 | 61.9 K to 60.7 K (-1.99 %) |
Oct 10 2018 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 2.13 | 1,686 | 3,589 | 79,080 | 80.8 K to 79.1 K (-2.09 %) |
Oct 10 2018 | OMED | OncoMed Pharmaceut ... | Stagg Robert | SVP, Clinical R&D | Sell | S | 2.13 | 1,686 | 3,589 | 41,597 | 43.3 K to 41.6 K (-3.90 %) |
Oct 10 2018 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | President & CEO | Sell | S | 2.13 | 2,296 | 4,888 | 57,122 | 59.4 K to 57.1 K (-3.86 %) |
Oct 10 2018 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Sell | S | 2.13 | 1,686 | 3,589 | 52,910 | 54.6 K to 52.9 K (-3.09 %) |
Jun 25 2018 | OMED | OncoMed Pharmaceut ... | WYZGA MICHAEL S | Director | Option Exercise | A | 2.55 | 15,000 | 38,250 | 15,000 | |
Jun 25 2018 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Option Exercise | A | 2.55 | 15,000 | 38,250 | 15,000 | |
Jun 25 2018 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Option Exercise | A | 2.55 | 15,000 | 38,250 | 15,000 | |
Jun 25 2018 | OMED | OncoMed Pharmaceut ... | KARSEN PERRY A | Director | Option Exercise | A | 2.55 | 15,000 | 38,250 | 15,000 | |
Jun 25 2018 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Option Exercise | A | 2.55 | 15,000 | 38,250 | 15,000 | |
Jun 25 2018 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Option Exercise | A | 2.55 | 15,000 | 38,250 | 15,000 | |
Jun 25 2018 | OMED | OncoMed Pharmaceut ... | Winningham Rick E | Director | Option Exercise | A | 2.55 | 15,000 | 38,250 | 15,000 | |
Apr 26 2018 | OMED | OncoMed Pharmaceut ... | Li Yvonne | See Remarks | Sell | S | 2.68 | 5,062 | 13,555 | 59,890 | 65 K to 59.9 K (-7.79 %) |
Apr 26 2018 | OMED | OncoMed Pharmaceut ... | Stagg Robert | SVP, Clinical R&D | Sell | S | 2.68 | 4,051 | 10,848 | 43,283 | 47.3 K to 43.3 K (-8.56 %) |
Apr 26 2018 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | President & CEO | Sell | S | 2.68 | 4,557 | 12,202 | 55,418 | 60 K to 55.4 K (-7.60 %) |
Apr 26 2018 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 2.68 | 4,051 | 10,848 | 76,766 | 80.8 K to 76.8 K (-5.01 %) |
Apr 26 2018 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Sell | S | 2.68 | 4,051 | 10,848 | 54,596 | 58.6 K to 54.6 K (-6.91 %) |
Mar 20 2018 | OMED | OncoMed Pharmaceut ... | Li Yvonne | See Remarks | Option Exercise | A | 2.98 | 75,000 | 223,500 | 75,000 | |
Mar 19 2018 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | President & CEO | Option Exercise | A | 2.98 | 125,000 | 372,500 | 125,000 | |
Feb 23 2018 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | President | Option Exercise | A | 2.23 | 125,000 | 278,750 | 125,000 | |
Jan 08 2018 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Option Exercise | A | 3.98 | 100,000 | 398,000 | 100,000 | |
Jan 08 2018 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Option Exercise | A | 3.98 | 100,000 | 398,000 | 100,000 | |
Jan 08 2018 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Option Exercise | A | 3.98 | 70,000 | 278,600 | 70,000 | |
Jan 08 2018 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Option Exercise | A | 3.98 | 70,000 | 278,600 | 70,000 | |
Oct 12 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Sell | S | 4.24 | 1,202 | 5,099 | 68,336 | 69.5 K to 68.3 K (-1.73 %) |
Oct 12 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Sell | S | 4.27 | 46 | 196 | 69,538 | 69.6 K to 69.5 K (-0.07 %) |
Oct 12 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 4.24 | 1,346 | 5,709 | 76,188 | 77.5 K to 76.2 K (-1.74 %) |
Oct 12 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 4.26 | 52 | 222 | 77,534 | 77.6 K to 77.5 K (-0.07 %) |
Oct 12 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Sell | S | 4.24 | 1,202 | 5,099 | 70,412 | 71.6 K to 70.4 K (-1.68 %) |
Oct 12 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Sell | S | 4.26 | 46 | 196 | 71,614 | 71.7 K to 71.6 K (-0.06 %) |
Oct 12 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 4.24 | 1,202 | 5,099 | 80,817 | 82 K to 80.8 K (-1.47 %) |
Oct 12 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 4.27 | 46 | 196 | 82,019 | 82.1 K to 82 K (-0.06 %) |
Oct 12 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Sell | S | 4.24 | 1,202 | 5,099 | 58,647 | 59.8 K to 58.6 K (-2.01 %) |
Oct 12 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Sell | S | 4.26 | 46 | 196 | 59,849 | 59.9 K to 59.8 K (-0.08 %) |
Oct 10 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Option Exercise | A | 4.36 | 50,000 | 218,000 | 50,000 | |
Oct 10 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Grant | A | 0.00 | 25,000 | 0 | 69,584 | 44.6 K to 69.6 K (+56.07 %) |
Oct 10 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Option Exercise | A | 4.36 | 50,000 | 218,000 | 50,000 | |
Oct 10 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Grant | A | 0.00 | 25,000 | 0 | 71,660 | 46.7 K to 71.7 K (+53.58 %) |
Oct 10 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Option Exercise | A | 4.36 | 36,666 | 159,864 | 36,666 | |
Oct 10 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Grant | A | 0.00 | 18,334 | 0 | 59,895 | 41.6 K to 59.9 K (+44.11 %) |
Oct 10 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Option Exercise | A | 4.36 | 36,666 | 159,864 | 36,666 | |
Oct 10 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Grant | A | 0.00 | 18,334 | 0 | 82,065 | 63.7 K to 82.1 K (+28.77 %) |
Jun 07 2017 | OMED | OncoMed Pharmaceut ... | KARSEN PERRY A | Director | Buy | P | 3.46 | 10,000 | 34,588 | 10,000 | 0 to 10 K |
Jun 02 2017 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Option Exercise | A | 3.30 | 15,000 | 49,500 | 15,000 | |
Jun 02 2017 | OMED | OncoMed Pharmaceut ... | KARSEN PERRY A | Director | Option Exercise | A | 3.30 | 15,000 | 49,500 | 15,000 | |
Jun 02 2017 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Option Exercise | A | 3.30 | 15,000 | 49,500 | 15,000 | |
Jun 02 2017 | OMED | OncoMed Pharmaceut ... | Lasky Laurence | Director | Option Exercise | A | 3.30 | 15,000 | 49,500 | 15,000 | |
Jun 02 2017 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Option Exercise | A | 3.30 | 15,000 | 49,500 | 15,000 | |
Jun 02 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Option Exercise | A | 3.30 | 15,000 | 49,500 | 15,000 | |
Jun 02 2017 | OMED | OncoMed Pharmaceut ... | Winningham Rick E | Director | Option Exercise | A | 3.30 | 15,000 | 49,500 | 15,000 | |
Jun 02 2017 | OMED | OncoMed Pharmaceut ... | WYZGA MICHAEL S | Director | Option Exercise | A | 3.30 | 15,000 | 49,500 | 15,000 | |
May 26 2017 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Buy | P | 3.37 | 34,614 | 116,639 | 185,709 | 151.1 K to 185.7 K (+22.91 %) |
May 26 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | S | 3.70 | 3,222 | 11,927 | 0 | 3.2 K to 0 (-100.00 %) |
May 26 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | S | 3.70 | 6,358 | 23,536 | 0 | 6.4 K to 0 (-100.00 %) |
May 26 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | S | 3.72 | 1,447 | 5,377 | 3,222 | 4.7 K to 3.2 K (-30.99 %) |
May 26 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | S | 3.72 | 2,853 | 10,601 | 6,358 | 9.2 K to 6.4 K (-30.97 %) |
May 25 2017 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Buy | P | 3.55 | 20,000 | 71,000 | 151,095 | 131.1 K to 151.1 K (+15.26 %) |
May 22 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | S | 3.70 | 2,519 | 9,324 | 4,669 | 7.2 K to 4.7 K (-35.04 %) |
May 22 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | S | 3.70 | 4,968 | 18,388 | 9,211 | 14.2 K to 9.2 K (-35.04 %) |
May 18 2017 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Buy | P | 3.49 | 23,507 | 82,061 | 131,095 | 107.6 K to 131.1 K (+21.85 %) |
May 18 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | S | 3.58 | 2,321 | 8,313 | 7,188 | 9.5 K to 7.2 K (-24.41 %) |
May 18 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | S | 3.58 | 4,579 | 16,401 | 14,179 | 18.8 K to 14.2 K (-24.41 %) |
May 15 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | J | 0.00 | 19,215 | 0 | 0 | 19.2 K to 0 (-100.00 %) |
May 15 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Sell | J | 0.00 | 1,990,783 | 0 | 0 | 2 M to 0 (-100.00 %) |
May 15 2017 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Buy | J | 0.00 | 55,929 | 0 | 121,020 | 65.1 K to 121 K (+85.92 %) |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Option Exercise | A | 3.73 | 60,000 | 223,800 | 60,000 | |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Grant | A | 0.00 | 20,000 | 0 | 77,225 | 57.2 K to 77.2 K (+34.95 %) |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Option Exercise | A | 3.73 | 60,000 | 223,800 | 60,000 | |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Grant | A | 0.00 | 20,000 | 0 | 44,584 | 24.6 K to 44.6 K (+81.35 %) |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | A | 3.77 | 135,000 | 508,950 | 135,000 | |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Grant | A | 0.00 | 45,000 | 0 | 77,586 | 32.6 K to 77.6 K (+138.10 %) |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Option Exercise | A | 3.73 | 67,500 | 251,775 | 67,500 | |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Grant | A | 0.00 | 22,500 | 0 | 45,437 | 22.9 K to 45.4 K (+98.09 %) |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Option Exercise | A | 3.73 | 60,000 | 223,800 | 60,000 | |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Grant | A | 0.00 | 20,000 | 0 | 63,301 | 43.3 K to 63.3 K (+46.19 %) |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Option Exercise | A | 3.73 | 60,000 | 223,800 | 60,000 | |
Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Grant | A | 0.00 | 20,000 | 0 | 41,561 | 21.6 K to 41.6 K (+92.76 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Sell | S | 9.06 | 5,711 | 51,731 | 22,937 | 28.6 K to 22.9 K (-19.94 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Sell | S | 8.87 | 43 | 381 | 28,648 | 28.7 K to 28.6 K (-0.15 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 9.06 | 5,711 | 51,731 | 43,301 | 49 K to 43.3 K (-11.65 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 8.87 | 43 | 381 | 49,012 | 49.1 K to 49 K (-0.09 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Sell | S | 9.06 | 5,711 | 51,731 | 24,584 | 30.3 K to 24.6 K (-18.85 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Sell | S | 8.87 | 43 | 382 | 30,295 | 30.3 K to 30.3 K (-0.14 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Sell | S | 9.06 | 5,711 | 51,731 | 57,225 | 62.9 K to 57.2 K (-9.07 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Sell | S | 8.87 | 43 | 381 | 62,936 | 63 K to 62.9 K (-0.07 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Sell | S | 9.06 | 4,284 | 38,805 | 21,561 | 25.8 K to 21.6 K (-16.58 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Sell | S | 8.87 | 32 | 284 | 25,845 | 25.9 K to 25.8 K (-0.12 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 9.06 | 6,425 | 58,199 | 32,586 | 39 K to 32.6 K (-16.47 %) |
Apr 05 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 8.87 | 48 | 426 | 39,011 | 39.1 K to 39 K (-0.12 %) |
Mar 17 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Option Exercise | M | 3.42 | 6,652 | 22,750 | 0 | |
Mar 17 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Sell | S | 10.00 | 6,652 | 66,520 | 25,877 | 32.5 K to 25.9 K (-20.45 %) |
Mar 17 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Buy | M | 3.42 | 6,652 | 22,750 | 32,529 | 25.9 K to 32.5 K (+25.71 %) |
Jan 11 2017 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Sell | J | 0.00 | 108,810 | 0 | 380,299 | 489.1 K to 380.3 K (-22.25 %) |
Jan 11 2017 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Sell | J | 0.00 | 305,122 | 0 | 1,119,905 | 1.4 M to 1.1 M (-21.41 %) |
Jan 11 2017 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Buy | J | 0.00 | 30,501 | 0 | 107,588 | 77.1 K to 107.6 K (+39.57 %) |
Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | M | 1.43 | 21,369 | 30,558 | 0 | |
Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | M | 1.43 | 21,369 | 30,558 | 21,369 | |
Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 8.52 | 21,369 | 181,957 | 37,323 | 58.7 K to 37.3 K (-36.41 %) |
Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Buy | M | 1.43 | 21,369 | 30,558 | 58,692 | 37.3 K to 58.7 K (+57.25 %) |
Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 8.17 | 21,369 | 174,602 | 37,323 | 58.7 K to 37.3 K (-36.41 %) |
Jan 09 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Buy | M | 1.43 | 21,369 | 30,558 | 58,692 | 37.3 K to 58.7 K (+57.25 %) |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Option Exercise | A | 7.66 | 65,000 | 497,900 | 65,000 | |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Option Exercise | M | 1.43 | 9,175 | 13,120 | 0 | |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Sell | S | 7.63 | 9,175 | 70,045 | 31,636 | 40.8 K to 31.6 K (-22.48 %) |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Buy | M | 1.43 | 9,175 | 13,120 | 40,811 | 31.6 K to 40.8 K (+29.00 %) |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Option Exercise | A | 7.66 | 55,000 | 421,300 | 55,000 | |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | A | 7.66 | 176,000 | 1,348,160 | 176,000 | |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Option Exercise | A | 7.66 | 65,000 | 497,900 | 65,000 | |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Option Exercise | A | 7.66 | 55,000 | 421,300 | 55,000 | |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Option Exercise | A | 7.66 | 55,000 | 421,300 | 55,000 | |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Option Exercise | M | 1.43 | 12,763 | 18,251 | 0 | |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Sell | S | 7.64 | 12,763 | 97,448 | 60,979 | 73.7 K to 61 K (-17.31 %) |
Jan 05 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Buy | M | 1.43 | 12,763 | 18,251 | 73,742 | 61 K to 73.7 K (+20.93 %) |
Nov 18 2016 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Option Exercise | M | 1.43 | 12,500 | 17,875 | 12,763 | |
Nov 18 2016 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Sell | S | 9.89 | 12,500 | 123,609 | 60,979 | 73.5 K to 61 K (-17.01 %) |
Nov 18 2016 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Buy | M | 1.43 | 12,500 | 17,875 | 73,479 | 61 K to 73.5 K (+20.50 %) |
Oct 12 2016 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Sell | J | 0.00 | 822 | 0 | 489,109 | 489.9 K to 489.1 K (-0.17 %) |
Oct 12 2016 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Sell | J | 0.00 | 3,287 | 0 | 1,425,027 | 1.4 M to 1.4 M (-0.23 %) |
Oct 11 2016 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Grant | A | 0.00 | 12,500 | 0 | 31,636 | 19.1 K to 31.6 K (+65.32 %) |
Oct 11 2016 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP & Co-CSO | Grant | A | 0.00 | 12,500 | 0 | 60,979 | 48.5 K to 61 K (+25.78 %) |
Oct 11 2016 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Grant | A | 0.00 | 14,000 | 0 | 37,323 | 23.3 K to 37.3 K (+60.03 %) |
Oct 11 2016 | OMED | OncoMed Pharmaceut ... | Gurney Austin | SVP & Co-CSO | Grant | A | 0.00 | 12,500 | 0 | 47,055 | 34.6 K to 47.1 K (+36.17 %) |
Oct 11 2016 | OMED | OncoMed Pharmaceut ... | Dupont Jakob | SVP & Chief Medical ... | Grant | A | 0.00 | 12,500 | 0 | 34,440 | 21.9 K to 34.4 K (+56.97 %) |
Oct 11 2016 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Grant | A | 0.00 | 12,500 | 0 | 30,338 | 17.8 K to 30.3 K (+70.08 %) |
Oct 11 2016 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | VP & General Counse ... | Grant | A | 0.00 | 12,500 | 0 | 25,877 | 13.4 K to 25.9 K (+93.44 %) |
Jun 24 2016 | OMED | OncoMed Pharmaceut ... | WYZGA MICHAEL S | Director | Option Exercise | A | 12.61 | 15,000 | 189,150 | 15,000 | |
Jun 24 2016 | OMED | OncoMed Pharmaceut ... | Winningham Rick E | Director | Option Exercise | A | 12.61 | 15,000 | 189,150 | 15,000 | |
Jun 24 2016 | OMED | OncoMed Pharmaceut ... | ROOT JONATHAN D | Director | Option Exercise | A | 12.61 | 15,000 | 189,150 | 15,000 | |
Jun 24 2016 | OMED | OncoMed Pharmaceut ... | Pollard-Knight Denise | Director | Option Exercise | A | 12.61 | 15,000 | 189,150 | 15,000 | |
Jun 24 2016 | OMED | OncoMed Pharmaceut ... | PAKIANATHAN DEEPIKA | Director | Option Exercise | A | 12.61 | 15,000 | 189,150 | 15,000 | |
Jun 24 2016 | OMED | OncoMed Pharmaceut ... | Lasky Laurence | Director | Option Exercise | A | 12.61 | 15,000 | 189,150 | 15,000 | |
Jun 24 2016 | OMED | OncoMed Pharmaceut ... | LASERSOHN JACK W | Director | Option Exercise | A | 12.61 | 15,000 | 189,150 | 15,000 | |
Jun 24 2016 | OMED | OncoMed Pharmaceut ... | KARSEN PERRY A | Director | Option Exercise | A | 12.61 | 15,000 | 189,150 | 15,000 |